General aspects and neuropathology of X-linked adrenoleukodystrophy
- PMID: 20626743
- PMCID: PMC8094714
- DOI: 10.1111/j.1750-3639.2010.00390.x
General aspects and neuropathology of X-linked adrenoleukodystrophy
Abstract
X-adrenoleukodystrophy (X-ALD) is a metabolic, peroxisomal disease affecting the nervous system, adrenal cortex and testis resulting from inactivating mutations in ABCD1 gene which encodes a peroxisomal membrane half-adenosine triphosphate (ATP)-binding cassette transporter, ABCD1 (or ALDP), whose defect is associated with impaired peroxisomal beta-oxidation and accumulation of saturated very long-chain fatty acids (VLCFA) in tissues and body fluids. Several phenotypes are recognized in male patients including cerebral ALD in childhood, adolescence or adulthood, adrenomyeloneuropathy (AMN), Addison's disease and, eventually, gonadal insufficiency. Female carriers might present with mild to severe myeloneuropathy that resembles AMN. There is a lack of phenotype-genotype correlations, as the same ABCD1 gene mutation may be associated with different phenotypes in the same family, suggesting that genetic, epigenetic, environmental and stochastic factors are probably contributory to the development and course of the disease. Degenerative changes, like those seen in pure AMN without cerebral demyelination, are characterized by loss of axons and secondary myelin in the long tracts of the spinal cord, possibly related to the impaired lipid metabolism of VLCFAs and the associated alterations (ie, oxidative damage). Similar lesions are encountered following inactivation of ABCD1 in mice (ABCD1(-)). A different and more aggressive phenotype is secondary to cerebral demyelination, very often accompanied by inflammatory changes in the white matter of the brain and associated with activation of T lymphocytes, CD1 presentation and increased levels of cytokines, gamma-interferon, interleukin (IL)-1alpha, IL-2 and IL-6, Granulocyte macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor-alpha, chemokines and chemokine receptors.
Figures
Similar articles
-
[X-linked adrenoleukodystrophy].Ann Endocrinol (Paris). 2007 Dec;68(6):403-11. doi: 10.1016/j.ando.2007.04.002. Epub 2007 May 29. Ann Endocrinol (Paris). 2007. PMID: 17532287 Review. French.
-
HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.J Lipid Res. 2011 Nov;52(11):2056-69. doi: 10.1194/jlr.M017491. Epub 2011 Sep 4. J Lipid Res. 2011. PMID: 21891797 Free PMC article.
-
X-linked adrenoleukodystrophy and primary adrenal insufficiency.Front Endocrinol (Lausanne). 2023 Nov 16;14:1309053. doi: 10.3389/fendo.2023.1309053. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38034003 Free PMC article. Review.
-
Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy.Hum Mol Genet. 2012 Mar 1;21(5):1062-77. doi: 10.1093/hmg/ddr536. Epub 2011 Nov 17. Hum Mol Genet. 2012. PMID: 22095690 Free PMC article.
-
Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy.Hum Mol Genet. 2005 May 15;14(10):1293-303. doi: 10.1093/hmg/ddi140. Epub 2005 Mar 30. Hum Mol Genet. 2005. PMID: 15800013
Cited by
-
Structural and functional insights of the human peroxisomal ABC transporter ALDP.Elife. 2022 Nov 14;11:e75039. doi: 10.7554/eLife.75039. Elife. 2022. PMID: 36374178 Free PMC article.
-
Isoprostanoid Plasma Levels Are Relevant to Cerebral Adrenoleukodystrophy Disease.Life (Basel). 2022 Jan 20;12(2):146. doi: 10.3390/life12020146. Life (Basel). 2022. PMID: 35207434 Free PMC article.
-
Typical and atypical phenotype and neuroimaging of X-linked adrenoleukodystrophy in a Chinese cohort.Neurol Sci. 2022 May;43(5):3255-3263. doi: 10.1007/s10072-021-05859-y. Epub 2022 Jan 8. Neurol Sci. 2022. PMID: 34997422
-
Florid Brain Calcification in a Child with X-Linked Adrenoleukodystrophy: What Does it Signify?Ann Indian Acad Neurol. 2021 Jul-Aug;24(4):620-622. doi: 10.4103/aian.AIAN_974_20. Epub 2021 Mar 18. Ann Indian Acad Neurol. 2021. PMID: 34728974 Free PMC article. No abstract available.
-
Pathophysiology of X-linked adrenoleukodystrophy.Biochimie. 2014 Mar;98(100):135-42. doi: 10.1016/j.biochi.2013.11.023. Epub 2013 Dec 4. Biochimie. 2014. PMID: 24316281 Free PMC article. Review.
References
-
- Asheuer M, Bieche I, Laurendeau I, Moser A, Hainque B, Vidaud M, Aubourg P (2005) Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X‐linked adrenoleukodystrophy. Hum Mol Genet 14:1293–1303. - PubMed
-
- Aubourg P (1996) X‐linked adrenoleukodystrophy. In: Handbook of Clinical Neurology, Vinken PJ, Bruyn GW, Moser HW (eds), pp. 447–483. Elsevier: Amsterdam.
-
- Aubourg P, Adamsbaum C, Lavallard‐Rousseau MC, Lemaitre A, Boureau F, Mayer M, Kalifa G (1992) Brain MRI and electrophysiologic abnormalities in preclinical and clinical adrenomyeloneuropathy. Neurology 42:85–91. - PubMed
-
- Aubourg P, Adamsbaum C, Lavallard‐Rousseau MC, Rocchiccioli F, Cartier N, Jambaque I et al (1993) A two‐year trial of oleic and erucic acids (“Lorenzo's oil”) as treatment for adrenomyeloneuropathy. N Engl J Med 329:745–752. - PubMed
-
- Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G, Naud‐Saudreau C et al (1990) Reversal of early neurologic and neuroradiologic manifestations of X‐linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 322:1860–1806. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
